AREDS2 logo
Home Page About Page Locations Page Operations Center Page (password) ForeseeeHome Study page
photo of eye chart   Welcome to

The Age-Related Eye Disease Study 2 (AREDS2) was a multi-center, randomized trial designed to assess the effects of oral supplementation of macular xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid) [DHA] and eicosapentaenoic acid [EPA] ) on the progression to advanced age-related macular degeneration (AMD).  An additional goal of the study was to assess whether forms of the AREDS nutritional supplement with reduced zinc and/or no beta-carotene works as well as the original supplement in reducing the risk of progression to advanced AMD.

Enrollment concluded in June 2008 successfully and participants were followed between five and six years. To learn more about the study, click here.

  Updated by The Emmes Corporation April 2018   |   Contact Us
Sponsored by the National Eye Institute   |    Contract HHSN263201300005C

National Eye Institute           Department of Health and Human Services         The EMMES Corporation